Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials

被引：0
|
作者：
Cynthia J. Girman
Ekopimo Ibia
Shailendra Menjoge
Carmen Mak
Joshua Chen
Anupam Agarwal
Bruce Binkowitz
机构：
[1] Merck Sharp and Dohme Corp,Dept. of Epidemiology
[2] Merck Sharp and Dohme Corp,undefined
[3] Boehringer-Ingelheim,undefined
[4] Merck Sharp and Dohme Corp,undefined
[5] Pfizer,undefined
[6] Merck Research Laboratories,undefined
来源：
Drug information journal : DIJ / Drug Information Association | 2011年 / 45卷
关键词：
Multiregional clinical trial; Endpoint; Hypothesis testing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Regulatory agencies in different parts of the world may have different requirements for end-points, which significantly affects the design and conduct of registrational multiregional clinical trials (MRCT). In particular, different health authorities may request or require different endpoints as primary or key secondary hypotheses in phase 3 MRCTs. In addition, differences between regions may involve the time point considered primary, patient populations analyzed, study design, or noninferiority margins.
引用
收藏
页码：587 / 594
页数：7
相关论文
共 50 条
  • [21] Endpoints of clinical trials in oncology
    Roila, F
    Del Favero, A
    Ballatori, E
    [J]. TUMORI JOURNAL, 1997, 83 (06): : S8 - S13
  • [22] Economic endpoints in clinical trials
    Cook, J
    Drummond, M
    Heyse, JF
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2004, 13 (02) : 157 - 176
  • [23] CLINICAL TRIALS WITH BIOLOGICAL ENDPOINTS
    Roth, A. D.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 37 - 37
  • [24] ENDPOINTS FOR CLINICAL TRIALS OF SARCOIDOSIS
    Baughman, R. P.
    Drent, M.
    Culver, D. A.
    Grutters, J. C.
    Handa, T.
    Humbert, M.
    Judson, M. A.
    Lower, E. E.
    Mana, J.
    Pereira, C. A.
    Prasse, A.
    Sulica, R.
    Valyere, D.
    Vucinic, V.
    Wells, A. U.
    [J]. SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2012, 29 (02) : 90 - 98
  • [25] Surrogate Endpoints in Clinical Trials
    Elliott, Michael R.
    [J]. ANNUAL REVIEW OF STATISTICS AND ITS APPLICATION, 2023, 10 : 75 - 96
  • [26] Regulatory acceptance of novel endpoints in oncology trials
    Pignatti, F.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 8 - 8
  • [27] Strategic inclusion of regions in multiregional clinical trials
    Song, Seung Yeon
    Chee, Deborah
    Kim, EunYoung
    [J]. CLINICAL TRIALS, 2019, 16 (01) : 98 - 105
  • [28] Hierarchical Linear Models for Multiregional Clinical Trials
    Kim, Saemina
    Kang, Seung-Ho
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (03): : 334 - 343
  • [29] Regional consistency assessment in multiregional clinical trials
    Li, Gang
    Quan, Hui
    Wang, Yining
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024,
  • [30] Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring endpoints in Clinical Trials
    Suwandi, Jessica S.
    Nikolic, Tatjana
    Roep, Bart O.
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
12345